Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06055439 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
A Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Chimeric Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
- 4
- Study locations
NCT06055439 is a Phase 1 study of Colorectal Cancer and Gastric Cancer that is actively recruiting participants, run by Chimeric Therapeutics. The registered enrollment target is 135 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06055439, a Phase 1 study of Colorectal Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Chimeric Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
Conditions Studied
Interventions
- BIOLOGICAL CHM-2101 CAR-T cells
Study Locations (4)
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago - Chicago
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06055439
The ClinicalTrials.gov registry entry for NCT06055439 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Chimeric Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which CHM-2101 CAR-T cells is the first listed.
NCT06055439 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06055439 about?
NCT06055439 is a clinical study titled "A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy". The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
What is the current status of trial NCT06055439?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2024-05-15. Estimated completion is 2027-05.
What conditions does trial NCT06055439 study?
This clinical trial studies the following conditions: Colorectal Cancer, Gastric Cancer, Neuroendocrine Tumors.
What interventions are being tested in trial NCT06055439?
The interventions under investigation include: CHM-2101 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT06055439?
This trial is sponsored by Chimeric Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06055439 being conducted?
This trial has 4 study locations across Georgia, Illinois, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.